Royalty Pharma Announces Dividend Increase
Royalty Pharma (RPRX) has announced a 5% increase in its quarterly dividend for the first quarter of 2025. The company will pay a dividend of $0.22 per Class A ordinary share, up from the previous quarter's dividend. The payment is scheduled for March 10, 2025, and shareholders must be on record by the close of business on February 21, 2025 to receive the dividend.
Royalty Pharma (RPRX) ha annunciato un aumento del 5% del suo dividendo trimestrale per il primo trimestre del 2025. L'azienda pagherà un dividendo di $0,22 per azione ordinaria di Classe A, rispetto al dividendo del trimestre precedente. Il pagamento è programmato per il 10 marzo 2025, e gli azionisti devono essere registrati entro la chiusura dell'attività il 21 febbraio 2025 per ricevere il dividendo.
Royalty Pharma (RPRX) ha anunciado un aumento del 5% en su dividendo trimestral para el primer trimestre de 2025. La compañía pagará un dividendo de $0.22 por acción ordinaria Clase A, un aumento respecto al dividendo del trimestre anterior. El pago está programado para el 10 de marzo de 2025, y los accionistas deben estar registrados antes del cierre de operaciones el 21 de febrero de 2025 para recibir el dividendo.
로열티 제약 (RPRX)은 2025년 첫 분기 이익 배당금을 5% 인상했다고 발표했습니다. 회사는 클래스 A 보통주당 $0.22의 배당금을 지급할 예정이며, 이는 이전 분기의 배당금보다 증가한 수치입니다. 지급 일자는 2025년 3월 10일로 예정되어 있으며, 주주들은 배당금을 받기 위해 2025년 2월 21일 업무 종료 시까지 등록되어 있어야 합니다.
Royalty Pharma (RPRX) a annoncé une augmentation de 5% de son dividende trimestriel pour le premier trimestre de 2025. L'entreprise versera un dividende de 0,22 $ par action ordinaire de Classe A, en hausse par rapport au dividende du trimestre précédent. Le paiement est prévu pour le 10 mars 2025, et les actionnaires doivent être enregistrés avant la fermeture des bureaux le 21 février 2025 pour recevoir le dividende.
Royalty Pharma (RPRX) hat eine 5%ige Erhöhung seiner vierteljährlichen Dividende für das erste Quartal 2025 bekannt gegeben. Das Unternehmen wird eine Dividende von 0,22 $ pro Klasse A Stammaktie zahlen, was eine Erhöhung gegenüber der Dividende des vorherigen Quartals darstellt. Die Zahlung ist für den 10. März 2025 geplant, und die Aktionäre müssen bis zum Ende des Geschäftstags am 21. Februar 2025 registriert sein, um die Dividende zu erhalten.
- 5% increase in quarterly dividend demonstrates financial strength
- Dividend increase signals management's confidence in cash flow sustainability
- None.
NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2025 of
The dividend will be paid on March 10, 2025 to shareholders of record at the close of business on February 21, 2025.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates. For more information, visit www.royaltypharma.com.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6637
ir@royaltypharma.com
FAQ
What is Royalty Pharma's new dividend amount for Q1 2025?
When is the ex-dividend date for RPRX's Q1 2025 dividend?
How much did RPRX increase its dividend in Q1 2025?
When will Royalty Pharma pay its Q1 2025 dividend?
